(±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-(bis-tetradecyloxy)-1-propanaminium | 191980-81-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-(bis-tetradecyloxy)-1-propanaminium
• 英文别名: N-(2-hydroxyethyl)-N,N-dimethaneyl-2,3-bis(tetradecanoxy)-1-propanylammonium；N-(2-hydroxyethaneyl)-N,N-dimethyl-2,3-bis(tetradecanoxy)-1-propylammonium；N-(2-hydroxyethyl)-N,N-dimethaneyl-2,3-bis(tetradecanoxy)-1-propylammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecanyl-oxy)-1-propylammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecanoxy)-1-propanylammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis{tetradecyloxy}-1-propane ammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecaneoxy)-1-propylammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecanoxy)-1-propylammonium；N-(hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propane ammonium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium；N-(2-hydroxyethyl)-N,N-dimethyl-2,3-di(tetradecanoxy)-1-propylammonium；2,3-di(tetradecanyloxy)propyl-(2-hydroxyethyl)-dimethylammonium；2,3-di(tetradecanoxy)propyl-(2-hydroxyethyl)-dimethylammonium；2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium；dimyristyl rosenthal inhibitor ether；DMRIE；N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium
• CAS: 191980-81-1
• 化学式: C₃₅H₇₄NO₃
• 分子量: 556.977
• InChiKey: UZLHBUQJHDTDRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.7
• 重原子数：
  39
• 可旋转键数：
  33
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-(bis-tetradecyloxy)-1-propanaminium 在 甲胩 、 三乙胺 作用下， 以 氯仿 为溶剂， 生成 DMRIE methyl carbamate
  参考文献：
  名称：

  Complex cationic lipids having quarternary nitrogens therein

  摘要：

  提供了具有衍生季铵头基的阳离子脂质体，其具有改进的细胞靶向能力和增强的转染效果，可用于向细胞中引入分子。

  公开号：

  US06670332B1

文献信息

• CORONAVIRUS VACCINE
  申请人：BioNTech RNA Pharmaceuticals GmbH

  公开号：EP3901261A1

  公开（公告）日：2021-10-27

  This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

  该披露涉及RNA领域，用于预防或治疗冠状病毒感染。具体来说，本披露涉及用于预防冠状病毒感染和诱导有效的冠状病毒抗原特异性免疫应答（如抗体和/或T细胞应答）的方法和药剂。具体而言，在一种实施方式中，本披露涉及通过向受试者给予编码SARS-CoV-2尖刺蛋白（S蛋白）表位的肽或蛋白的RNA来诱导免疫应答，特别是在受试者中诱导对冠状病毒S蛋白的免疫应答，即编码疫苗抗原的疫苗RNA。
• Amine Cationic Lipids and Uses Thereof
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US20140371293A1

  公开（公告）日：2014-12-18

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。具体而言，这些化合物包括一类具有胺基团的阳离子脂质，例如氨基-胺或氨基-酰胺基团。这些脂质化合物可用于体内或体外传递一个或多个药物（例如，多聚阴离子荷载物或反义荷载物，如RNAi药物）。
• TREATMENT INVOLVING INTERLEUKIN-2 (IL2) AND INTERFERON (IFN)
  申请人：BIONTECH SE

  公开号：US20220143144A1

  公开（公告）日：2022-05-12

  The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.

  本公开涉及增强免疫效应细胞的方法和药剂，特别是对介白质-2（IL2）作出反应的免疫效应细胞，例如效应T细胞（如CD8+ T细胞）。具体而言，本公开涉及的方法包括向受试者给予包含IL2或其功能变体的多肽或编码包含IL2或其功能变体的多肽的多核苷酸和包含I型干扰素（IFN）或其功能变体的多肽或编码包含I型干扰素或其功能变体的多肽的多核苷酸。
• COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1842558A1

  公开（公告）日：2007-10-10

  The present invention has its object to provide a composition for suppressing the expression of a target gene and the like, and provides a composition, comprising an RNA-encapsulated liposome which comprises complex particles comprising as constituent components a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles, wherein constituent components of the lipid membrane can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible, and the like.

  本发明的目的是提供一种用于抑制目的基因等表达的组合物，本发明提供了一种组合物，该组合物包括RNA包封脂质体，该脂质体由复合微粒组成，复合微粒的组成成分包括引线微粒和RNA，RNA包括由目的基因mRNA的15至30个连续核苷酸组成的序列和与该序列互补的序列、和用于包覆复合物颗粒的脂质膜，其中脂质膜的组成成分可溶于极性有机溶剂中，极性有机溶剂可包含在液体中，其浓度使脂质膜的组成成分可分散，复合物颗粒可分散，等等。
• P.ariasi polypeptides, P.perniciosus polypeptides and methods of use
  申请人：The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services

  公开号：EP2158917A1

  公开（公告）日：2010-03-03

  Substantially purified salivary P. ariasi and P. pemiciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. pemiciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.

  本研究公开了基本纯化的唾液腺嗜血杆菌多肽和 Pemiciosus 多肽，以及编码这些多肽的多核苷酸。还公开了包括 P. ariasi 和 P. pemiciosus 多核苷酸的载体和宿主细胞。在一个实施方案中，公开了一种诱导对沙蝇唾液免疫应答的方法。在其他实施方案中，公开了治疗或预防利什曼病的方法。